OBJECTIVE: We describe a case of Cushing's syndrome due to ectopic ACTH secretion, where the only potential source on conventional imaging was a tiny benign-appearing lung nodule, which failed to take up radiolabelled octreotide. DESIGN AND METHODS: To determine whether the patient might respond to therapeutic administration of octreotide, a test dose was given. RESULTS: Compared to ACTH and cortisol levels on a control day, the levels following the test dose of octreotide were lower. Subsequent therapeutic administration of subcutaneous octreotide normalised urine free cortisol, with symptomatic improvement, pending evaluation for surgery. Eventual resection of the lung nodule resulted in cure of hypercortisolism. Histological examination of the resected specimen confirmed bronchial carcinoid staining positive for ACTH. CONCLUSIONS: This is one of the few cases described where ectopic ACTH secretion secondary to bronchial carcinoid responded to somatostatin analogue therapy. The case was also unusual in that the tumour responded despite not taking up radiolabelled octreotide.
OBJECTIVE: We describe a case of Cushing's syndrome due to ectopic ACTH secretion, where the only potential source on conventional imaging was a tiny benign-appearing lung nodule, which failed to take up radiolabelled octreotide. DESIGN AND METHODS: To determine whether the patient might respond to therapeutic administration of octreotide, a test dose was given. RESULTS: Compared to ACTH and cortisol levels on a control day, the levels following the test dose of octreotide were lower. Subsequent therapeutic administration of subcutaneous octreotide normalised urine free cortisol, with symptomatic improvement, pending evaluation for surgery. Eventual resection of the lung nodule resulted in cure of hypercortisolism. Histological examination of the resected specimen confirmed bronchial carcinoid staining positive for ACTH. CONCLUSIONS: This is one of the few cases described where ectopic ACTH secretion secondary to bronchial carcinoid responded to somatostatin analogue therapy. The case was also unusual in that the tumour responded despite not taking up radiolabelled octreotide.
Authors: D J Torpy; C C Chen; N Mullen; J L Doppman; J A Carrasquillo; G P Chrousos; L K Nieman Journal: J Clin Endocrinol Metab Date: 1999-04 Impact factor: 5.958
Authors: P Loli; F Vignati; E Grossrubatscher; P Dalino; M Possa; F Zurleni; G Lomuscio; O Rossetti; M Ravini; A Vanzulli; C Bacchetta; C Galli; D Valente Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: B L Wajchenberg; B B Mendonca; B Liberman; M A Pereira; P C Carneiro; A Wakamatsu; M A Kirschner Journal: Endocr Rev Date: 1994-12 Impact factor: 19.871
Authors: S W Lamberts; L J Hofland; P M van Koetsveld; J C Reubi; H A Bruining; W H Bakker; E P Krenning Journal: J Clin Endocrinol Metab Date: 1990-09 Impact factor: 5.958
Authors: X Bertagna; C Favrod-Coune; H Escourolle; P Beuzeboc; B Christoforov; F Girard; J P Luton Journal: J Clin Endocrinol Metab Date: 1989-05 Impact factor: 5.958
Authors: S Tsagarakis; M Christoforaki; H Giannopoulou; F Rondogianni; I Housianakou; C Malagari; D Rontogianni; I Bellenis; N Thalassinos Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: B Mariniello; I Finco; P Sartorato; A Patalano; M Iacobone; V Guzzardo; A Fassina; F Mantero Journal: J Endocrinol Invest Date: 2010-10-27 Impact factor: 4.256